Table 1 Study population characteristics stratified according to treatments.
Moderate-to-severe disease | Mild disease n = 822,906 | P valuea | |||||
|---|---|---|---|---|---|---|---|
Biologic n = 1817 | Methotrexate n = 1153 | Cyclosporine n = 755 | Mixed conventional systemic n = 679 | Phototherapy n = 83,838 | |||
Male sex, n (%) | 1215 (66.9) | 654 (56.7) | 469 (62.1) | 512 (75.4) | 43,939 (52.4) | 43,2497 (52.6) | < .001 |
Age, y (mean ± SD) | 37.1 ± 13.1 | 43.0 ± 16.2 | 44.9 ± 16.8 | 48.6 ± 16.1 | 40.5 ± 15.0 | 46.9 ± 16.1 | < .001 |
Range in year, n | |||||||
20–30 | 670 | 316 | 189 | 103 | 26,344 | 152,601 | |
31–40 | 458 | 247 | 135 | 117 | 20,265 | 164,007 | |
41–50 | 390 | 216 | 150 | 152 | 15,613 | 172,519 | |
51–60 | 214 | 187 | 140 | 129 | 11,822 | 156,957 | |
61–70 | 61 | 116 | 78 | 118 | 6,369 | 101,953 | |
71- | 24 | 71 | 63 | 60 | 3,425 | 74,869 | |
Baseline comorbidities | |||||||
Hypertension, n (%) | 428 (23.6) | 284 (24.6) | 219 (29.0) | 242 (35.6) | 14,993 (17.9) | 203,745 (24.8) | < .001 |
Diabetes mellitus, n (%) | 283 (15.6) | 193 (16.7) | 184 (24.4) | 156 (23.0) | 10,029 (12.0) | 124,556 (15.1) | < .001 |
Dyslipidemia, n (%) | 645 (35.5) | 338 (29.3) | 236 (31.3) | 209 (30.8) | 15,195 (18.1) | 168,981 (20.5) | < .001 |
End-stage renal disease, n (%) | 4 (0.2) | 2 (0.2) | 21 (2.8) | 8 (1.2) | 688 (0.8) | 2,879 (0.3) | < .001 |
Person-years (mean ± SD) | 2.99 ± 0.01 | 2.98 ± 0.02 | 2.95 ± 0.06 | 3.22 ± 0.55 | 2.98 ± 0.02 | 2.97 ± 0.03 | |
